BR9808285A - Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus - Google Patents

Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus

Info

Publication number
BR9808285A
BR9808285A BR9808285-0A BR9808285A BR9808285A BR 9808285 A BR9808285 A BR 9808285A BR 9808285 A BR9808285 A BR 9808285A BR 9808285 A BR9808285 A BR 9808285A
Authority
BR
Brazil
Prior art keywords
zinc
crystals
free
free insulin
insulin crystals
Prior art date
Application number
BR9808285-0A
Other languages
English (en)
Inventor
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9808285A publication Critical patent/BR9808285A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"CRISTAIS DE INSULINA ISENTOS DE ZINCO, FORMULAçãO TERAPêUTICA EM Pó, PROCESSO PARA A PREPARAçãO DE CRISTAIS DE INSULINA ISENTOS DE ZINCO, USO DE CRISTAIS ISENTOS DE ZINCO, E, PROCESSO PARA O TRATAMENTO DE DIABETES MELLITUS" Os cristais de insulina isentos de zinco tendo um diâmetro abaixo de 10 um apropriado para administração pulmonar são descritos. Os descritos tem uma tendência reduzida a associar em agregados em pó seco.
BR9808285-0A 1997-03-20 1998-03-20 Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus BR9808285A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK31797 1997-03-20
PCT/DK1998/000109 WO1998042749A1 (en) 1997-03-20 1998-03-20 Zinc free insulin crystals for use in pulmonary compositions

Publications (1)

Publication Number Publication Date
BR9808285A true BR9808285A (pt) 2000-05-16

Family

ID=8092195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808285-0A BR9808285A (pt) 1997-03-20 1998-03-20 Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus

Country Status (17)

Country Link
US (2) US20070093411A1 (pt)
EP (2) EP1005490B1 (pt)
JP (1) JP3764174B2 (pt)
KR (1) KR20000076419A (pt)
CN (1) CN1259142A (pt)
AT (1) ATE321783T1 (pt)
AU (1) AU742591B2 (pt)
BR (1) BR9808285A (pt)
CA (1) CA2283705A1 (pt)
DE (1) DE69834028T2 (pt)
ES (1) ES2260832T3 (pt)
HU (1) HUP0000547A3 (pt)
IL (1) IL131796A0 (pt)
NO (1) NO994520L (pt)
PL (1) PL335777A1 (pt)
RU (1) RU2198181C2 (pt)
WO (1) WO1998042749A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500933B1 (en) 1997-09-05 2002-12-31 Altus Biologics Inc. Methods of preparing carbohydrate crosslinked glycoprotein crystals
ATE397013T1 (de) 1997-09-05 2008-06-15 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
AU757991B2 (en) * 1998-04-27 2003-03-13 Altus Pharmaceuticals, Inc. Stabilized protein crystals, formulations containing them and methods of making them
DE19903125B4 (de) * 1999-01-27 2006-01-05 Sanofi-Aventis Deutschland Gmbh Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga
EP1173482A1 (en) * 1999-04-27 2002-01-23 Eli Lilly And Company Insulin crystals for pulmonary administration
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
DE10250297A1 (de) * 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
EP2264065B1 (en) * 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
US7658721B2 (en) 2004-01-16 2010-02-09 Biodel Inc. Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
KR100798333B1 (ko) * 2005-08-03 2008-01-28 고려대학교 산학협력단 락토오스 운반체와 혼합건조된 폐 전달용 인슐린미세결정분말
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CN102471368A (zh) * 2009-08-11 2012-05-23 拜康有限公司 色谱方法及其纯化的化合物
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
BR112017000175B1 (pt) * 2014-07-08 2023-11-21 Amphastar Pharmaceuticals,Inc. Método de preparação de uma insulina inalável adequada para a liberação pulmonar e partículas de insulina micronizadas
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
WO2017032797A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341403B1 (en) 2015-08-25 2022-01-05 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN108026156A (zh) 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
CN106749616B (zh) * 2016-12-19 2021-09-03 华润昂德生物药业有限公司 B30位苏氨酸缺失人胰岛素晶体的制备方法
CN109957001B (zh) * 2017-12-26 2022-11-18 甘李药业股份有限公司 甘赖脯胰岛素结晶的制备方法
PL238016B1 (pl) * 2018-07-06 2021-06-28 Bioton Spolka Akcyjna Krystaliczna, bezcynkowa postać insuliny glargine i sposób jej otrzymywania
TWI773009B (zh) 2019-12-11 2022-08-01 丹麥商諾佛 儂迪克股份有限公司 新穎之胰島素類似物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE3327928A1 (de) * 1983-08-03 1985-02-21 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
KR100419037B1 (ko) * 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität

Also Published As

Publication number Publication date
RU2198181C2 (ru) 2003-02-10
KR20000076419A (ko) 2000-12-26
EP1627642A2 (en) 2006-02-22
US20090311326A9 (en) 2009-12-17
WO1998042749A1 (en) 1998-10-01
JP2001506272A (ja) 2001-05-15
ES2260832T3 (es) 2006-11-01
IL131796A0 (en) 2001-03-19
US20070093411A1 (en) 2007-04-26
US20070292520A1 (en) 2007-12-20
DE69834028T2 (de) 2006-12-07
EP1627642A3 (en) 2006-04-19
PL335777A1 (en) 2000-05-22
NO994520D0 (no) 1999-09-17
NO994520L (no) 1999-09-17
CN1259142A (zh) 2000-07-05
ATE321783T1 (de) 2006-04-15
HUP0000547A3 (en) 2002-11-28
EP1005490B1 (en) 2006-03-29
EP1005490A1 (en) 2000-06-07
DE69834028D1 (de) 2006-05-18
JP3764174B2 (ja) 2006-04-05
CA2283705A1 (en) 1998-10-01
HUP0000547A2 (hu) 2000-08-28
AU6612098A (en) 1998-10-20
AU742591B2 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
BR9808285A (pt) Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus
AU560179B2 (en) Hypoglycemic thiazolidinedione derivatives
BR9910928A (pt) Composto, processo para a prepará-lo, uso do mesmo, formulação, e, processo para a profilaxia e/ou tratamento de condições clinicas associadas com resistência a insulina
HUP0201654A2 (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (ppar) alpha, their preparation and pharmaceutical composition containing the same
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
ES2139678T5 (es) Uso de eritropoyetina para la preparacion de una composicion farmaceutica para administracion pulmonar o inhalacion.
EA199900454A1 (ru) Стабильные порошковые препараты, находящиеся в стекловидном состоянии
EE04238B1 (et) Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias
BR0312633A (pt) Composto, uso do composto, composição farmacêutica, processo para a preparação de um composto
NO893239D0 (no) Farmasoeytisk preparat for behandling av diabetes mellitus.
DE69830584D1 (de) 2-(iminomethyl)aminophenyl-derivate, deren herstellung, verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
CA2056653A1 (en) Preparation for transdermal drug administration
IE64850B1 (en) Therapeutically active substituted benzimidazole and process for its preparation
SG64693G (en) Nicorandil-containing preparation for injection
AR015894A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
SE8601457D0 (sv) Compositions of liposomes and b?712-receptor active substances for inhalation
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
KR910016734A (ko) 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도
EP0373613A3 (en) Pyridine-3-percarboxylic acid monopersulfate
SE8204872L (sv) Farmaceutiska preparat, innefattande humant insulin, human c-peptid och humant proinsulin
AU5744890A (en) Association of l-5-hydroxy-tryptophane with benserazide as a pharmaceutical composition to be used in the treatment of problems of balance and ataxia, cerebellar or other, irrespective of origin, and its use for the preparation of said composition
IT1186775B (it) Derivati nuobosidici aventi proprieta' antierpetiche,composizioni farmaceutiche che li contengono e procedimento per la preparazione degli ingredienti attivi
FR2654728B2 (fr) Derives d'acides pyridone carboxyliques azetidinyl substitues, leur preparation et leur application en tant que medicament.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1888 DE 13/03/2007.